Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
Schey AS, Morris J, Maguire A, Dhanasiri S. Quantifying the burden of multiple myeloma across Europe. Blood. 2016;128(22):5960.
Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl_4):iv52–61.
CAS PubMed Article Google Scholar
Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374(9686):324–39.
Caers J, Vande broek I, De Raeve H, Michaux L, Trullemans F, Schots R, et al. Multiple myeloma—an update on diagnosis and treatment. Eur J Haematol. 2008;81(5):329–43.
Rajkumar SV. Updated diagnostic criteria and staging system for multiple myeloma. Am Soc Clin Oncol Educ Book. 2016;35:e418–23.
Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia. 2009;23(10):1691–7.
CAS PubMed Article Google Scholar
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.
Rajkumar SV. Multiple myeloma: every year a new standard? Hematol Oncol. 2019;37(Suppl 1):62–5.
PubMed PubMed Central Article Google Scholar
Abdi J, Chen G, Chang H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget. 2013;4(12):2186–207.
PubMed PubMed Central Article Google Scholar
Di Marzo L, Desantis V, Solimando AG, Ruggieri S, Annese T, Nico B, et al. Microenvironment drug resistance in multiple myeloma: emerging new players. Oncotarget. 2016;7(37):60698–711.
PubMed PubMed Central Article Google Scholar
Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615–27.
CAS PubMed Article Google Scholar
Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia. 2003;17(6):1175–82.
CAS PubMed Article Google Scholar
Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, et al. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood. 2012;120(16):3260–70.
CAS PubMed PubMed Central Article Google Scholar
Abraham J, Salama NN, Azab AK. The role of P-glycoprotein in drug resistance in multiple myeloma. Leuk Lymphoma. 2015;56(1):26–33.
CAS PubMed Article Google Scholar
Papadas A, Asimakopoulos F. Mechanisms of resistance in multiple myeloma. Handb Exp Pharmacol. 2017;249:251–88.
Kawano Y, Moschetta M, Manier S, Glavey S, Görgün GT, Roccaro AM, et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev. 2015;263(1):160–72.
Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM. Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol. 2012;2012: 157496.
CAS PubMed PubMed Central Article Google Scholar
Moschetta M, Kawano Y, Sacco A, Belotti A, Ribolla R, Chiarini M, et al. Bone marrow stroma and vascular contributions to myeloma bone homing. Curr Osteoporos Rep. 2017;15(5):499–506.
Reagan MR, Ghobrial IM. Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin Cancer Res. 2012;18(2):342–9.
CAS PubMed Article Google Scholar
Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7(8):585–98.
CAS PubMed Article Google Scholar
Brown GK. Glucose transporters: structure, function and consequences of deficiency. J Inherit Metab Dis. 2000;23(3):237–46.
CAS PubMed Article Google Scholar
El Arfani C, De Veirman K, Maes K, De Bruyne E, Menu E. Metabolic features of multiple myeloma. Int J Mol Sci. 2018;19(4):1200.
PubMed Central Article CAS Google Scholar
Alfarouk KO, Verduzco D, Rauch C, Muddathir AK, Adil HH, Elhassan GO, et al. Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question. Oncoscience. 2014;1(12):777–802.
PubMed PubMed Central Article Google Scholar
Zheng J. Energy metabolism of cancer: glycolysis versus oxidative phosphorylation (review). Oncol Lett. 2012;4(6):1151–7.
CAS PubMed PubMed Central Article Google Scholar
Pfeiffer T, Schuster S, Bonhoeffer S. Cooperation and competition in the evolution of ATP-producing pathways. Science. 2001;292(5516):504–7.
CAS PubMed Article Google Scholar
Newsholme P, Procopio J, Lima MM, Pithon-Curi TC, Curi R. Glutamine and glutamate—their central role in cell metabolism and function. Cell Biochem Funct. 2003;21(1):1–9.
CAS PubMed Article Google Scholar
Choi YK, Park KG. Targeting glutamine metabolism for cancer treatment. Biomol Ther (Seoul). 2018;26(1):19–28.
Chen J, Zaal EA, Berkers CR, Ruijtenbeek R, Garssen J, Redegeld FA. Omega-3 fatty acids DHA and EPA reduce bortezomib resistance in multiple myeloma cells by promoting glutathione degradation. Cells. 2021;10(9):2287.
CAS PubMed PubMed Central Article Google Scholar
Halama A. Metabolomics in cell culture—a strategy to study crucial metabolic pathways in cancer development and the response to treatment. Arch Biochem Biophys. 2014;564:100–9.
CAS PubMed Article Google Scholar
Moreadith RW, Lehninger AL. The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD(P)+-dependent malic enzyme. J Biol Chem. 1984;259(10):6215–21.
CAS PubMed Article Google Scholar
Wellen KE, Lu C, Mancuso A, Lemons JM, Ryczko M, Dennis JW, et al. The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. Genes Dev. 2010;24(24):2784–99.
CAS PubMed PubMed Central Article Google Scholar
Curthoys NP, Watford M. Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr. 1995;15:133–59.
CAS PubMed Article Google Scholar
Brinkmann JF, Abumrad NA, Ibrahimi A, van der Vusse GJ, Glatz JF. New insights into long-chain fatty acid uptake by heart muscle: a crucial role for fatty acid translocase/CD36. Biochem J. 2002;367(Pt 3):561–70.
CAS PubMed PubMed Central Article Google Scholar
Masarwi M, DeSchiffart A, Ham J, Reagan MR. Multiple myeloma and fatty acid metabolism. JBMR Plus. 2019;3(3): e10173.
PubMed PubMed Central Article CAS Google Scholar
Xiong J. Fatty acid oxidation in cell fate determination. Trends Biochem Sci. 2018;43(11):854–7.
CAS PubMed PubMed Central Article Google Scholar
Yan F, Zhao H, Zeng Y. Lipidomics: a promising cancer biomarker. Clin Transl Med. 2018;7(1):21.
PubMed PubMed Central Article Google Scholar
Grunt TW. Interacting cancer machineries: cell signaling, lipid metabolism, and epigenetics. Trends Endocrinol Metab. 2018;29(2):86–98.
CAS PubMed Article Google Scholar
Beloribi-Djefaflia S, Vasseur S, Guillaumond F. Lipid metabolic reprogramming in cancer cells. Oncogenesis. 2016;5: e189.
CAS PubMed PubMed Central Article Google Scholar
Peck B, Schulze A. Lipid desaturation - the next step in targeting lipogenesis in cancer? FEBS J. 2016;283(15):2767–78.
留言 (0)